

# Global Uveitis Treatment Market - 2025 -2033

<https://marketpublishers.com/r/GCF793119688EN.html>

Date: October 2025

Pages: 180

Price: US\$ 4,350.00 (Single User License)

ID: GCF793119688EN

## Abstracts

### Uveitis Treatment Market Size & Industry Outlook

The global uveitis treatment market size reached US\$ 742.09million with rise of US\$779.75million in 2024 is expected to reach US\$ 1,258.35million by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033.

One of major growing factor in this market is increasing awareness and early diagnosis of ocular disorders. For instance, a 2024 study published in Ophthalmology highlighted that the implementation of widespread screening programs and the use of advanced imaging techniques, such as optical coherence tomography (OCT), led to earlier detection of uveitis in high-risk populations. Early diagnosis allows for timely intervention, reducing the risk of vision loss and improving treatment outcomes. This heightened awareness among healthcare providers and patients is accelerating the adoption of available therapies, thereby supporting market expansion.

### Key Highlights

North America dominates the uveitis treatment market with the largest revenue share of 43.5% in 2024.

The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 8.1% over the forecast period.

Based on drug class, corticosteroids segmented the market with the largest revenue share of 38.1% in 2024.

The major market players in the AbbVie Inc, Bausch Health Companies / Bausch + Lomb, EyePoint Pharmaceuticals, Inc, Santen Pharmaceutical Co.,

Ltd, Alimera Sciences, Ocular Therapeutix, Inc, Ophthotech Corporation and among others.

## Market Dynamics

**Drivers:** The rising prevalence of autoimmune and inflammatory disorders is significantly driving the uveitis treatment market growth

The rising prevalence of autoimmune and inflammatory disorders is significantly influencing the global uveitis treatment market. Uveitis, an intraocular inflammatory condition, is often associated with systemic autoimmune diseases such as rheumatoid arthritis, lupus, and Crohn's disease. These conditions can lead to non-infectious uveitis, which is more challenging to treat and often requires long-term management strategies.

These trends underscore the critical role that the rising prevalence of autoimmune and inflammatory disorders plays in shaping the uveitis treatment landscape, driving both market growth and the development of more specialized therapeutic options.

For instance, NCBI estimates indicate that the global incidence and prevalence of autoimmune diseases are rising annually by approximately 19.1% and 12.5%, respectively.

**Restraints:** Limited access to treatments in developing regions are hampering the growth of the Uveitis Treatment market

Limited access to advanced uveitis treatments in developing regions remains a significant challenge for the global market. In many low- and middle-income countries, patients face barriers such as high treatment costs, inadequate healthcare infrastructure, and a shortage of trained specialists. These limitations restrict timely diagnosis and access to innovative therapies, including biologics and targeted immunosuppressants, resulting in suboptimal disease management and poorer patient outcomes. Consequently, this disparity hampers overall market growth and underscores the need for improved healthcare accessibility and affordability in these regions.

## Segmentation Analysis

The global uveitis treatment market is segmented based on uveitis type, drug class,

route of administration, distribution channel, and region.

#### Drug Class:

The corticosteroids from drug class segment to dominate the uveitis treatment market with a 38.1% share in 2024

The corticosteroids segment plays a pivotal role in the uveitis treatment market, serving as the first-line therapy for reducing inflammation and preventing vision loss. available in topical, periocular, and intravitreal forms, corticosteroids help manage both anterior and posterior uveitis. intravitreal implants like Retisert and Yutiq provide sustained drug delivery, minimizing the need for frequent administration. the segment benefits from strong clinical efficacy, well-established usage, and wide availability, making it a major contributor to market growth globally.

For instance, A study published in Ocular Immunology and Inflammation 2025, evaluated 1,475 patients across multiple uveitis clinics in the U.S., comparing the efficacy of corticosteroids alone, corticosteroids combined with conventional immunosuppressants (methotrexate, mycophenolate mofetil, azathioprine, leflunomide), and corticosteroids in combination with biologic therapies (TNF inhibitors such as adalimumab and infliximab). The results demonstrated that patients receiving corticosteroids alongside immunosuppressants or biologics experienced faster and more sustained resolution of inflammation compared to corticosteroid monotherapy.

#### Route of Administration:

The oral segment is estimated to have a 54.1% of the uveitis treatment market share in 2024

The oral segment, primarily comprising immunosuppressants such as methotrexate, cyclosporine, and mycophenolate, addresses moderate to severe cases of non-infectious uveitis. oral therapies offer systemic immunomodulation, benefiting patients with multi-site inflammation or refractory disease. this segment is gaining traction due to increasing adoption of biologics in combination with oral immunosuppressants, expanded clinical guidelines, and growing awareness among physicians, driving its share in the overall uveitis treatment market.

#### Geographical Analysis

North America dominates the global uveitis treatment market with a 43.5% in 2024

The North American uveitis treatment market is fueled by robust healthcare infrastructure, high awareness, ongoing clinical trials and advanced therapies. Early biologics and intravitreal implants adoption, with major players like AbbVie, Bausch Health, and Eye Point Pharmaceuticals, and favorable reimbursement policies accelerate market expansion. For instance, in September 2024, Priovant Therapeutics has enrolled the first patients in the CLARITY Phase 3 study for brepocitinib in non-anterior non-infectious uveitis. The FDA has granted Brepocitinib Fast Track Designation for NIU, a process designed to expedite the development and review of drugs for serious conditions.

The US market for biologics, particularly Adalimumab, is driven by a large patient population, high prevalence of autoimmune and inflammatory disorders, robust clinical trial activity, insurance coverage, innovative corticosteroid implants, strong regulatory support, and investment in ophthalmology research.

Europe is the second region after North America which is expected to dominate the global uveitis treatment market with a 34.5% in 2024

Europe's market for ocular immunotherapy is growing due to increasing ocular inflammation disorders and acceptance of corticosteroid implants and biologic therapies. Collaboration between governments, academic centers, and pharmaceutical companies enhances innovation. Reimbursement policies in Germany and France provide wider patient access, while a well-established ophthalmology network strengthens treatment adoption. The UK market is driven by NHS support, a strong network of specialist eye clinics, clinical research programs, patient-centric initiatives, and participation in multinational trials.

For instance, in May 2025, A study by researchers from the University of Bristol in England has published guidelines for uveitis detection and treatment, highlighting the development of improved treatment options for patients with the inflammatory eye disease.

The Asia Pacific region is the fastest-growing region in the global uveitis treatment market ,with a CAGR of 8.1% in 2024

The Asia Pacific market is driven by a rising burden of ocular infections, increasing awareness of eye health, and expanding access to biologics and steroid implants.

Rapid healthcare infrastructure development, global investments, and a growing middle-class population drive market adoption.

In Japan, with high healthcare standards, strong government support, and early adoption of innovative ophthalmic drugs, is also fostering regional growth in the uveitis treatment segment.

For instance, Uveitis is a major ophthalmic concern in Japan, with 200 cases per 100,000 individuals, accounting for 3.2% of all new ophthalmic disease cases in 2024. This significant patient pool encourages adoption of advanced therapies such as biologics and corticosteroid implants, driving growth in the uveitis treatment market.

### Competitive Landscape

Top companies in the uveitis treatment market include AbbVie Inc, Bausch Health Companies / Bausch + Lomb, Eye Point Pharmaceuticals, Inc, Santen Pharmaceutical Co., Ltd, Alimera Sciences, Ocular Therapeutix, Inc, Ophthotech Corporation

**AbbVie Inc:** AbbVie Inc is a leading player in the global uveitis treatment market, known for its flagship biologic Humira (Adalimumab), which is one of the few monoclonal antibodies approved for non-infectious intermediate, posterior, and panuveitis. The company's targeted therapy reduces long-term corticosteroid use, strengthening its position as a market leader in immunology and ophthalmology. AbbVie leverages its clinical data, patient access programs, and global commercial reach to drive the adoption of biologic therapies for uveitis.

### Key Developments:

In March 2025, ANI Pharmaceuticals has received FDA approval for an expanded label for Iluvien, which includes treatment for chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). This expansion, along with a stronger partnership with Seigfried, aims to improve supply security and access for patients in need.

The global uveitis treatment market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

## Contents

### 1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

### 2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Uveitis Type
- 2.4. Snippet by Drug Class
- 2.5. Snippet by Route of Administration
- 2.6. Snippet by Distribution Channel
- 2.7. Snippet by Region

### 3. DYNAMICS

- 3.1. Impacting Factors
  - 3.1.1. Drivers
    - 3.1.1.1. Rising Prevalence of Autoimmune and Inflammatory Disorders
    - 3.1.1.2. Growing Adoption of Biologics and Targeted Therapies
  - 3.1.2. Restraints
    - 3.1.2.1. Limited Access to Treatments in Developing Regions
    - 3.1.2.2. High Cost of Advanced Biologics
  - 3.1.3. Opportunity
    - 3.1.3.1. Increasing Clinical Trials and Pipeline of Novel Therapies
    - 3.1.3.2. Expansion of Strategic Collaborations and Partnerships

### 4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
  - 4.1.1. Emerging Pioneers and Prominent Players
  - 4.1.2. Established Leaders with the Largest Marketing Brand
  - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape

- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. Asia Pacific
- 4.3.4. South America
- 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
- 4.5. Patent Analysis
- 4.6. Unmet Needs and Gaps
- 4.7. Recommended Strategies for Market Entry and Expansion
- 4.8. Pricing Analysis and Price Dynamics

## **5. UVEITIS TREATMENT MARKET, BY UVEITIS TYPE**

- 5.1. Introduction
  - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  - 5.1.2. Market Attractiveness Index, By Uveitis Type
- 5.2. Anterior\*
  - 5.2.1. Introduction
  - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Intermediate
- 5.4. Posterior
- 5.5. Panuveitis

## **6. UVEITIS TREATMENT MARKET, BY DRUG CLASS**

- 6.1. Introduction
  - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  - 6.1.2. Market Attractiveness Index, By Drug Class
- 6.2. Corticosteroids\*
  - 6.2.1. Introduction
  - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Immunosuppressants
- 6.4. Monoclonal Antibodies
- 6.5. Antibiotics
- 6.6. Others

## **7. UVEITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION**

- 7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

7.1.2. Market Attractiveness Index, ByRoute of Administration

7.2. Oral\*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Intravenous

## **8. UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL**

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

8.1.2. Market Attractiveness Index, By Distribution Channel

8.2. Hospital Pharmacies\*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Retail Pharmacies

## **9. UVEITIS TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES**

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.7.1. U.S.

9.2.7.2. Canada

9.2.7.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.7.1. Germany
  - 9.3.7.2. UK
  - 9.3.7.3. France
  - 9.3.7.4. Spain
  - 9.3.7.5. Italy
  - 9.3.7.6. Rest of Europe
- 9.4. Asia-Pacific
  - 9.4.1. Introduction
  - 9.4.2. Key Region-Specific Dynamics
  - 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  - 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  - 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  - 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  - 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 9.4.7.1. China
    - 9.4.7.2. India
    - 9.4.7.3. Japan
    - 9.4.7.4. South Korea
    - 9.4.7.5. Rest of Asia-Pacific
- 9.5. South America
  - 9.5.1. Introduction
  - 9.5.2. Key Region-Specific Dynamics
  - 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  - 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  - 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  - 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  - 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 9.5.7.1. Brazil
    - 9.5.7.2. Argentina
    - 9.5.7.3. Rest of South America
- 9.6. Middle East and Africa

- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

## **10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING**

- 10.1. Competitive Overview and Key Market Players
- 10.2. Market Share Analysis and Positioning Matrix
- 10.3. Strategic Partnerships, Mergers & Acquisitions
- 10.4. Key Developments in Product Portfolios and Innovations
- 10.5. Company Benchmarking

## **11. COMPANY PROFILES**

- 11.1. AbbVie Inc\*
  - 11.1.1. Company Overview
  - 11.1.2. Product Portfolio
    - 11.1.2.1. Product Description
    - 11.1.2.2. Product Key Performance Indicators (KPIs)
  - 11.1.3. Financial Overview
    - 11.1.3.1. Company Revenue
    - 11.1.3.2. Geographical Revenue Shares
    - 11.1.3.3. Revenue Forecasts
  - 11.1.4. Key Developments
    - 11.1.4.1. Mergers & Acquisitions
    - 11.1.4.2. Key Product Development Activities
    - 11.1.4.3. Regulatory Approvals, etc.
    - 11.1.4.4. SWOT Analysis
- 11.2. Bausch Health Companies / Bausch + Lomb
- 11.3. EyePoint Pharmaceuticals, Inc.
- 11.4. Santen Pharmaceutical Co., Ltd
- 11.5. Alimera Sciences
- 11.6. Ocular Therapeutix, Inc
- 11.7. Ophthotech Corporation ( LIST NOT EXHAUSTIVE )

## **12. ASSUMPTIONS AND RESEARCH METHODOLOGY**

- 12.1. Data Collection Methods
- 12.2. Data Triangulation
- 12.3. Forecasting Techniques
- 12.4. Data Verification and Validation

## **13. APPENDIX**

- 13.1. About Us and Services
- 13.2. Contact Us

## List Of Tables

### LIST OF TABLES

Table 1 Global Uveitis Treatment Market Value, By Uveitis Type, 2025, 2029 & 2033 (US\$ Million)

Table 2 Global Uveitis Treatment Market Value, By Drug Class, 2025, 2029 & 2033 (US\$ Million)

Table 3 Global Uveitis Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US\$ Million)

Table 4 Global Uveitis Treatment Market Value, By Distribution Channel, 2025, 2029 & 2033 (US\$ Million)

Table 5 Global Uveitis Treatment Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)

Table 6 Global Uveitis Treatment Market Value, By Uveitis Type, 2025, 2029 & 2033 (US\$ Million)

Table 7 Global Uveitis Treatment Market Value, By Uveitis Type, 2022-2033 (US\$ Million)

Table 8 Global Uveitis Treatment Market Value, By Drug Class, 2025, 2029 & 2033 (US\$ Million)

Table 9 Global Uveitis Treatment Market Value, By Drug Class, 2022-2033 (US\$ Million)

Table 10 Global Uveitis Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US\$ Million)

Table 11 Global Uveitis Treatment Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 12 Global Uveitis Treatment Market Value, By Distribution Channel, 2025, 2029 & 2033 (US\$ Million)

Table 13 Global Uveitis Treatment Market Value, By Distribution Channel, 2022-2033 (US\$ Million)

Table 14 Global Uveitis Treatment Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)

Table 15 Global Uveitis Treatment Market Value, By Region, 2022-2033 (US\$ Million)

Table 16 North America Uveitis Treatment Market Value, By Uveitis Type, 2022-2033 (US\$ Million)

Table 17 North America Uveitis Treatment Market Value, By Drug Class, 2022-2033 (US\$ Million)

Table 18 North America Uveitis Treatment Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 19 North America Uveitis Treatment Market Value, By Distribution Channel, 2022-2033 (US\$ Million)

Table 20 North America Uveitis Treatment Market Value, By Country, 2022-2033 (US\$ Million)

Table 21 Europe Uveitis Treatment Market Value, By Uveitis Type, 2022-2033 (US\$ Million)

Table 22 Europe Uveitis Treatment Market Value, By Drug Class, 2022-2033 (US\$ Million)

Table 23 Europe Uveitis Treatment Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 24 Europe Uveitis Treatment Market Value, By Distribution Channel, 2022-2033 (US\$ Million)

Table 25 Europe Uveitis Treatment Market Value, By Country, 2022-2033 (US\$ Million)

Table 26 Asia-Pacific Uveitis Treatment Market Value, By Uveitis Type, 2022-2033 (US\$ Million)

Table 27 Asia-Pacific Uveitis Treatment Market Value, By Drug Class, 2022-2033 (US\$ Million)

Table 28 Asia-Pacific Uveitis Treatment Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 29 Asia-Pacific Uveitis Treatment Market Value, By Distribution Channel, 2022-2033 (US\$ Million)

Table 30 Asia-Pacific Uveitis Treatment Market Value, By Country, 2022-2033 (US\$ Million)

Table 31 South America Uveitis Treatment Market Value, By Uveitis Type, 2022-2033 (US\$ Million)

Table 32 South America Uveitis Treatment Market Value, By Drug Class, 2022-2033 (US\$ Million)

Table 33 South America Uveitis Treatment Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 34 South America Uveitis Treatment Market Value, By Distribution Channel, 2022-2033 (US\$ Million)

Table 35 South America Uveitis Treatment Market Value, By Country, 2022-2033 (US\$ Million)

Table 36 Middle East and Africa Uveitis Treatment Market Value, By Uveitis Type, 2022-2033 (US\$ Million)

Table 37 Middle East and Africa Uveitis Treatment Market Value, By Drug Class, 2022-2033 (US\$ Million)

Table 38 Middle East and Africa Uveitis Treatment Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 39 Middle East and Africa Uveitis Treatment Market Value, By Distribution Channel, 2022-2033 (US\$ Million)

Table 40 Middle East and Africa Uveitis Treatment Market Value, By Country, 2022-2033 (US\$ Million)

Table 41 AbbVie Inc: Overview

Table 42 AbbVie Inc: Product Portfolio

Table 43 AbbVie Inc: Key Developments

Table 44 Bausch Health Companies / Bausch + Lomb: Overview

Table 45 Bausch Health Companies / Bausch + Lomb: Product Portfolio

Table 46 Bausch Health Companies / Bausch + Lomb: Key Developments

Table 47 EyePoint Pharmaceuticals, Inc.: Overview

Table 48 EyePoint Pharmaceuticals, Inc.: Product Portfolio

Table 49 EyePoint Pharmaceuticals, Inc.: Key Developments

Table 50 Santen Pharmaceutical Co., Ltd: Overview

Table 51 Santen Pharmaceutical Co., Ltd: Product Portfolio

Table 52 Santen Pharmaceutical Co., Ltd: Key Developments

Table 53 Alimera Sciences: Overview

Table 54 Alimera Sciences: Product Portfolio

Table 55 Alimera Sciences: Key Developments

Table 56 Ocular Therapeutix, Inc: Overview

Table 57 Ocular Therapeutix, Inc: Product Portfolio

Table 58 Ocular Therapeutix, Inc: Key Developments

Table 59 Ophthotech Corporation: Overview

Table 60 Ophthotech Corporation: Product Portfolio

Table 61 Ophthotech Corporation: Key Developments

## List Of Figures

### LIST OF FIGURES

Figure 1 Global Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 2 Global Uveitis Treatment Market Share, By Uveitis Type, 2024 & 2033 (%)

Figure 3 Global Uveitis Treatment Market Share, By Drug Class, 2024 & 2033 (%)

Figure 4 Global Uveitis Treatment Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 5 Global Uveitis Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 6 Global Uveitis Treatment Market Share, By Region, 2024 & 2033 (%)

Figure 7 Global Uveitis Treatment Market Y-o-Y Growth, By Uveitis Type, 2023-2033 (%)

Figure 8 Anterior Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 9 Intermediate Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 10 Posterior Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 11 Panuveitis Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 12 Global Uveitis Treatment Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 13 Corticosteroids Drug Class in Global Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 14 Immunosuppressants Drug Class in Global Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 15 Monoclonal Antibodies Drug Class in Global Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 16 Antibiotics Drug Class in Global Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 17 Others Drug Class in Global Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 18 Global Uveitis Treatment Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 19 Oral Route of Administration in Global Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 20 Intravenous Route of Administration in Global Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 21 Global Uveitis Treatment Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 22 Hospital Pharmacies Distribution Channel in Global Uveitis Treatment Market

Value, 2022-2033 (US\$ Million)

Figure 23 Retail Pharmacies Distribution Channel in Global Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 24 Global Uveitis Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 25 North America Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 26 North America Uveitis Treatment Market Share, By Uveitis Type, 2024 & 2033 (%)

Figure 27 North America Uveitis Treatment Market Share, By Drug Class, 2024 & 2033 (%)

Figure 28 North America Uveitis Treatment Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 29 North America Uveitis Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 30 North America Uveitis Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 31 Europe Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 32 Europe Uveitis Treatment Market Share, By Uveitis Type, 2024 & 2033 (%)

Figure 33 Europe Uveitis Treatment Market Share, By Drug Class, 2024 & 2033 (%)

Figure 34 Europe Uveitis Treatment Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 35 Europe Uveitis Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 36 Europe Uveitis Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 37 Asia-Pacific Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 38 Asia-Pacific Uveitis Treatment Market Share, By Uveitis Type, 2024 & 2033 (%)

Figure 39 Asia-Pacific Uveitis Treatment Market Share, By Drug Class, 2024 & 2033 (%)

Figure 40 Asia-Pacific Uveitis Treatment Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 41 Asia-Pacific Uveitis Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 42 Asia-Pacific Uveitis Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 43 South America Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 44 South America Uveitis Treatment Market Share, By Uveitis Type, 2024 & 2033 (%)

Figure 45 South America Uveitis Treatment Market Share, By Drug Class, 2024 & 2033 (%)

Figure 46 South America Uveitis Treatment Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 47 South America Uveitis Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 48 South America Uveitis Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 49 Middle East and Africa Uveitis Treatment Market Value, 2022-2033 (US\$ Million)

Figure 50 Middle East and Africa Uveitis Treatment Market Share, By Uveitis Type, 2024 & 2033 (%)

Figure 51 Middle East and Africa Uveitis Treatment Market Share, By Drug Class, 2024 & 2033 (%)

Figure 52 Middle East and Africa Uveitis Treatment Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 53 Middle East and Africa Uveitis Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 54 AbbVie Inc: Financials

Figure 55 Bausch Health Companies / Bausch + Lomb: Financials

Figure 56 EyePoint Pharmaceuticals, Inc.: Financials

Figure 57 Santen Pharmaceutical Co., Ltd: Financials

Figure 58 Alimera Sciences: Financials

Figure 59 Ocular Therapeutix, Inc: Financials

Figure 60 Ophthotech Corporation: Financials

## I would like to order

Product name: Global Uveitis Treatment Market - 2025 -2033

Product link: <https://marketpublishers.com/r/GCF793119688EN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCF793119688EN.html>